What is Alnylam Pharmaceuticals's deferred tax assets?

Alnylam Pharmaceuticals (ALNY) reported deferred tax assets of $116.96M in Q1 2026.

How has Alnylam Pharmaceuticals's deferred tax assets changed year-over-year?

Alnylam Pharmaceuticals's deferred tax assets increased by 9.1% year-over-year, from $107.22M to $116.96M.

What is the long-term trend for Alnylam Pharmaceuticals's deferred tax assets?

Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's deferred tax assets has grown at a 253.2% compound annual growth rate (CAGR), from $10.10M to $125.98M.

What does deferred tax assets mean?

Future tax savings expected from accounting and tax reporting differences.

Non-Current Assets

Deferred Tax Assets

Alnylam Pharmaceuticals Deferred Tax Assets decreased by 7.2% to $116.96M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $107.22M to $116.96M. Over 2 years (FY 2023 to FY 2025), Deferred Tax Assets shows an upward trend with a 253.2% CAGR.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Assets

CategoryRisk

SignalContext dependent

VolatilityModerate

First reportedQ3 2019

Last reportedQ4 2025

How to read this metric

An increase may signal future tax relief, while a decrease suggests the utilization of tax assets or valuation allowance adjustments.

Detailed definition

This represents the future tax benefits that the company expects to realize due to temporary differences between the boo...

Peer comparison

Common in global mining; peers with significant capital expenditures often hold substantial deferred tax assets.

Metric ID: non_current_assets_deferred_income_tax_assets_net

Historical Data

7 periods

	Q4 '23	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$10.10M	$116.86M	$107.22M	$104.36M	$98.56M	$125.98M	$116.96M
QoQ Change	—	>999%	-8.2%	-2.7%	-5.6%	+27.8%	-7.2%
YoY Change	—	>999%	—	—	—	+7.8%	+9.1%

Range$10.10M – $125.98M

CAGR+411.8%

Avg YoY Growth+357.9%

Median YoY Growth+9.1%

Deferred Tax Assets at Other Companies

Regeneron PharmaceuticalsREGN View metric

Gilead SciencesGILD View metric

Johnson & JohnsonJNJ View metric

Vertex PharmaceuticalsVRTX View metric

Frequently Asked Questions

What is Alnylam Pharmaceuticals's deferred tax assets?: Alnylam Pharmaceuticals (ALNY) reported deferred tax assets of $116.96M in Q1 2026.
How has Alnylam Pharmaceuticals's deferred tax assets changed year-over-year?: Alnylam Pharmaceuticals's deferred tax assets increased by 9.1% year-over-year, from $107.22M to $116.96M.
What is the long-term trend for Alnylam Pharmaceuticals's deferred tax assets?: Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's deferred tax assets has grown at a 253.2% compound annual growth rate (CAGR), from $10.10M to $125.98M.
What does deferred tax assets mean?: Future tax savings expected from accounting and tax reporting differences.